Paramount's Updated Warner Bros. Bid, US Healthcare, and Economic Policy on SquawkPod

Paramount's Amended Warner Bros. Discovery Offer

• 🤝 Paramount SkyDance has amended its offer for Warner Bros. Discovery (WBD) for the sixth time, aiming to outbid Netflix.
• 💰 Key investor Larry Ellison is now providing a personal guarantee of $41 billion for the equity financing, addressing WBD's concerns about financial backing.
• ⚖️ Paramount argues its all-cash offer of $30 per share is superior to Netflix's proposal, which involves stock and a spin-off company, citing regulatory clarity and value certainty.
• 🎯 The amended offer includes six key changes, such as not revoking the Ellison Family Trust during the transaction and increasing the regulatory reverse termination fee to $5.8 billion.

US Healthcare System and Vaccine Policy

• 💉 Secretary Robert F. Kennedy Jr. is reportedly considering a Danish model for the US vaccine schedule, which recommends fewer shots than the current US list.
• 🏥 Former FDA Commissioner Dr. Scott Gottlieb explains that Denmark accepts higher rates of hospitalization and deaths by not vaccinating against certain diseases like flu, hepatitis B, and chickenpox.
• 🔬 Gottlieb argues that these diseases are not benign, citing significant pediatric hospitalizations and deaths historically, and that reducing vaccinations would lead to their resurgence.
• ⚖️ The debate around vaccine schedules is linked to potential liability protection under the Vaccine Injury Compensation Program (VICP), with some trial lawyers seeking to sue manufacturers directly.

Economic Policy and Tariffs

• 📈 Kevin Hassett, former top economic adviser, believes the Supreme Court will likely not call for widespread tariff refunds even if they rule against the president's tariff regime, due to administrative complexity.
• 🌐 Hassett suggests the White House has other mechanisms to implement tariffs, and the current discussion focuses on how they were implemented.
• 💊 Regarding drug pricing, mandatory rebates for Medicare drugs are being implemented based on price differentials between the US and Europe, though the impact is expected to be limited.
• 🚀 A significant aspect is companies agreeing to launch new drugs at a